Advertisement
Screener

NeoGenomics, Inc. (NEO) Sales Revenue, Services, Other (Deprecated 2018-01-31)

2.9 / 5 stars · 42/72 Roast Me

NeoGenomics, Inc. Sales Revenue, Services, Other (Deprecated 2018-01-31)

NeoGenomics, Inc. (NEO) reported Sales Revenue, Services, Other (Deprecated 2018-01-31) of $360.17 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-13.

Discontinued › Expense Statement › Operating Expenses

us-gaap:SalesRevenueServicesGross · last filed 2018-03-13

  • NeoGenomics, Inc. sales revenue, services, other (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $96.94M, a 17.01% decline year-over-year.
  • NeoGenomics, Inc. sales revenue, services, other (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $85.43M, a 25.65% decline year-over-year.
  • NeoGenomics, Inc. sales revenue, services, other (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $93.86M, a 27.37% decline year-over-year.
  • NeoGenomics, Inc. sales revenue, services, other (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $83.94M, a 36.76% decline year-over-year.
  • NeoGenomics, Inc. sales revenue, services, other (deprecated 2018-01-31) for fiscal 2017 was $360.17M, a 27.04% decline from fiscal 2016.
  • NeoGenomics, Inc. sales revenue, services, other (deprecated 2018-01-31) for fiscal 2016 was $493.68M, a 119.36% increase from fiscal 2015.
  • NeoGenomics, Inc. sales revenue, services, other (deprecated 2018-01-31) for fiscal 2015 was $225.06M, a 0.27% increase from fiscal 2014.
  • NeoGenomics, Inc. sales revenue, services, other (deprecated 2018-01-31) for fiscal 2014 was $224.46M, a 29.16% increase from fiscal 2013.
Period endSales Revenue, Services, Other (Deprecated 2018-01-31) 3 monthSales Revenue, Services, Other (Deprecated 2018-01-31) 6 monthSales Revenue, Services, Other (Deprecated 2018-01-31) 9 monthSales Revenue, Services, Other (Deprecated 2018-01-31) 12 month
2017-12-31$96.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13
$182.37M
derived: sum of 2 quarters · filed 2018-03-13
$276.24M
derived: sum of 3 quarters · filed 2018-03-13
$360.17M
10-K · filed 2018-03-13
2017-09-30$85.43M
10-Q · filed 2017-11-13
$179.29M
derived: sum of 2 quarters · filed 2017-11-13
$263.23M
10-Q · filed 2017-11-13
$380.05M
derived: sum of 4 quarters · filed 2018-03-13
2017-06-30$93.86M
10-Q · filed 2017-08-07
$177.80M
10-Q · filed 2017-08-07
$294.62M
derived: sum of 3 quarters · filed 2018-03-13
$409.52M
derived: sum of 4 quarters · filed 2018-03-13
2017-03-31$83.94M
10-Q · filed 2017-05-09
$200.76M
derived: sum of 2 quarters · filed 2018-03-13
$315.66M
derived: sum of 3 quarters · filed 2018-03-13
$444.90M
derived: sum of 4 quarters · filed 2018-03-13
2016-12-31$116.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13
$231.72M
derived: sum of 2 quarters · filed 2018-03-13
$360.96M
derived: sum of 3 quarters · filed 2018-03-13
$493.68M
10-K · filed 2018-03-13
2016-09-30$114.90M
10-Q · filed 2017-11-13
$244.14M
derived: sum of 2 quarters · filed 2017-11-13
$376.86M
10-Q · filed 2017-11-13
$434.39M
derived: sum of 4 quarters · filed 2018-03-13
2016-06-30$129.24M
10-Q · filed 2017-08-07
$261.95M
10-Q · filed 2017-08-07
$319.49M
derived: sum of 3 quarters · filed 2018-03-13
$376.68M
derived: sum of 4 quarters · filed 2018-03-13
2016-03-31$132.72M
10-Q · filed 2017-05-09
$190.25M
derived: sum of 2 quarters · filed 2018-03-13
$247.44M
derived: sum of 3 quarters · filed 2018-03-13
$304.15M
derived: sum of 4 quarters · filed 2018-03-13
2015-12-31$57.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13
$114.72M
derived: sum of 2 quarters · filed 2018-03-13
$171.43M
derived: sum of 3 quarters · filed 2018-03-13
$225.06M
10-K · filed 2018-03-13
2015-09-30$57.19M
10-Q · filed 2016-11-07
$113.89M
derived: sum of 2 quarters · filed 2016-11-07
$167.53M
10-Q · filed 2016-11-07
$232.32M
derived: sum of 4 quarters · filed 2017-03-14
2015-06-30$56.70M
10-Q · filed 2016-08-05
$110.33M
10-Q · filed 2016-08-05
$175.13M
derived: sum of 3 quarters · filed 2017-03-14
$235.79M
derived: sum of 4 quarters · filed 2017-03-14
2015-03-31$53.63M
10-Q · filed 2016-05-10
$118.43M
derived: sum of 2 quarters · filed 2017-03-14
$179.09M
derived: sum of 3 quarters · filed 2017-03-14
$236.89M
derived: sum of 4 quarters · filed 2017-03-14
2014-12-31$64.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14
$125.45M
derived: sum of 2 quarters · filed 2017-03-14
$183.26M
derived: sum of 3 quarters · filed 2017-03-14
$224.46M
10-K · filed 2017-03-14
2014-09-30$60.66M
10-Q · filed 2015-11-06
$118.47M
derived: sum of 2 quarters · filed 2015-07-31
$159.66M
10-Q · filed 2015-11-06
$203.82M
derived: sum of 4 quarters · filed 2016-04-18
2014-06-30$57.80M
10-Q · filed 2015-07-31
$99.00M
10-Q · filed 2015-07-31
$143.16M
derived: sum of 3 quarters · filed 2016-04-18
$188.32M
derived: sum of 4 quarters · filed 2016-04-18
2014-03-31$41.20M
10-Q · filed 2015-05-11
$85.36M
derived: sum of 2 quarters · filed 2016-04-18
$130.52M
derived: sum of 3 quarters · filed 2016-04-18
$173.66M
derived: sum of 4 quarters · filed 2016-04-18
2013-12-31$44.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-18
$89.32M
derived: sum of 2 quarters · filed 2016-04-18
$132.46M
derived: sum of 3 quarters · filed 2016-04-18
$173.78M
10-K · filed 2016-04-18
2013-09-30$45.16M
10-Q · filed 2014-11-04
$88.30M
derived: sum of 2 quarters · filed 2014-11-04
$129.63M
10-Q · filed 2014-11-04
$169.09M
derived: sum of 4 quarters · filed 2015-03-03
2013-06-30$43.14M
10-Q · filed 2014-07-29
$84.47M
10-Q · filed 2014-07-29
$123.93M
derived: sum of 3 quarters · filed 2015-03-03
$158.73M
derived: sum of 4 quarters · filed 2015-03-03
2013-03-31$41.33M
10-Q · filed 2014-05-12
$80.78M
derived: sum of 2 quarters · filed 2015-03-03
$115.59M
derived: sum of 3 quarters · filed 2015-03-03
2012-12-31$39.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03
$74.27M
derived: sum of 2 quarters · filed 2015-03-03
$157.59M
10-K · filed 2015-03-03
2012-09-30$34.81M
10-Q · filed 2013-10-30
$118.13M
10-Q · filed 2013-10-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
20/20 Biolabs, Inc. (AIDX)United States$0.005B